https://www.selleckchem.com/pr....oducts/cm272-cm-272.
To conduct a network meta-analysis of randomised controlled trials to determine the optimal clinical choice of first-line therapy for patients with ALK receptor tyrosine kinase ( ) gene rearrangement non-small cell lung cancer (NSCLC). Clinical trials in patients with histologically confirmed gene rearrangement NSCLC, that included ALK inhibitors as first-line therapy, were identified using database searches. A Bayesian network meta-analysis was conducted to calculate the efficacy and safety of the included first-line treatments. N
Like
Comment
Share
